CLINICAL ROLE -
Therapies Under Investigation for Waldenström Macroglobulinemia
The exciting therapies in the pipeline that are thought to target novel mechanisms in Waldenström macroglobulinemia.
BTK Inhibitor Dose Adjustments in Waldenström Macroglobulinemia
What pharmacists need to know about BTK inhibitor drug activity, dosing, and interactions in Waldenström macroglobulinemia.
BTK Inhibitor Treatment Selection in Waldenström Macroglobulinemia
An overview of BTK inhibitors available as first-line therapy for Waldenström macroglobulinemia, and variables that impact treatment selection and the switching of agents throughout the course of therapy.
Approaches to Managing Progressive Waldenstrom Macroglobulinemia
Recommendations for classifying and treating patients with progressive Waldenstrom macroglobulinemia.
Waldenstrom Macroglobulinemia: First-Line Treatment Decisions
The top considerations of hematologists and oncologists when selecting first-line treatment for patients with Waldenstrom macroglobulinemia.
Novel Therapies for Waldenstrom Macroglublinemia
What pharmacists need to know about the adoption of novel targeted therapies for Waldenstrom macroglobulinemia into regular clinical practice.
When to Initiate Therapy for Waldenstrom Macroglublinemia
The criteria used by hematologists and oncologists to guide decisions to initiate therapy for Waldenstrom macroglobulinemia vs monitor patients with active surveillance.
The Molecular Pathogenesis of Waldenstrom Macroglublinemia
An overview of the types of biomarkers that play a role in the manifestation of Waldenstrom macroglobulinemia.
Waldenstrom Macroglobulinemia Vs Other Lymphomas
The characteristics of Waldenstrom macroglobulinemia that distinguish the disease from other types of lymphomas.
2 Commerce Drive Cranbury, NJ 08512